Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Avecho Biotechnology Limited ( (AU:AVE) ).
Avecho Biotechnology has announced nearing the completion of recruitment for its pivotal Phase III clinical trial for a CBD-enhanced capsule aimed at treating insomnia, with 190 out of the targeted 210 participants already dosed. The successful outcome of this trial could position Avecho as a leader in the Australian CBD market, particularly since regulatory changes allow over-the-counter CBD sales. This progress represents a critical step towards gaining market approvals and tapping into the rapidly growing sleep aids industry.
More about Avecho Biotechnology Limited
Avecho Biotechnology Limited is an Australian-based company specializing in human and animal health products utilizing its proprietary Tocopheryl Phosphate Mixture (TPM®) drug delivery system. Its flagship product is a CBD-enhanced soft-gel capsule designed to improve drug absorption, currently in Phase III clinical development for treating insomnia.
Average Trading Volume: 10,076,957
Current Market Cap: A$33.06M
For a thorough assessment of AVE stock, go to TipRanks’ Stock Analysis page.